Coeptis Therapeutics is a biopharmaceutical
company developing innovative cell therapy
platforms for patients with cancer.
Coeptis has acquired two Phase 1 clinical stage assets from Deverra Therapeutics. These exciting new treatments utilize a novel source of off-the-shelf natural killer cells, with one trial targeting relapsed or refractory acute myeloid leukemia (AML) and the other targeting hospitalized respiratory infections. The agreement also includes preclinical programs that use macrophages to treat patients suffering from hematologic and solid tumor cancer.
Coeptis has acquired two Phase 1 clinical stage assets from Deverra Therapeutics. These exciting new treatments utilize a novel source of off-the-shelf natural killer cells, with one trial targeting relapsed or refractory acute myeloid leukemia (AML) and the other targeting hospitalized respiratory infections. The agreement also includes preclinical programs that use macrophages to treat patients suffering from hematologic and solid tumor cancer.
OUR Mission:
TO IMPROVE outcomes for patients with cancer
Involves innovative cell therapy platforms
Learn More
Coeptis Therapeutics is a biopharmaceutical company developing innovative cell therapy platforms for patients with cancer
Learn More
For more information regarding Press Releases, stock information
Learn More
Various immunotherapies for CD38+ tumors are designed to find and kill cells that express the CD38 antigen; therefore, CD38+ NK cells are likely to become collateral damage and with their eradication, the overall anti-tumor response is suboptimal.
To protect CD38+ Natural Killer (NK) cells so that functional disease-targeting NK cells will not be eradicated, enabling their co-existence with CD38 targeting therapies, and thus allowing tumor killing and immune surveillance.
Modified NK cells that are co-administered with select monoclonal antibodies and/or other CD38 targeting immunotherapies are in pre-clinical development to enhance and maximize tumor kill via combinatorial approaches otherwise not possible.
Various immunotherapies for CD38+ tumors are designed to find and kill cells that express the CD38 antigen; therefore, CD38+ NK cells are likely to become collateral damage and with their eradication, the overall anti-tumor response is suboptimal.
To protect CD38+ Natural Killer (NK) cells so that functional disease-targeting NK cells will not be eradicated, enabling their co-existence with CD38 targeting therapies, and thus allowing tumor killing and immune surveillance.
Modified NK cells that are co-administered with select monoclonal antibodies and/or other CD38 targeting immunotherapies are in pre-clinical development to enhance and maximize tumor kill via combinatorial approaches otherwise not possible.
Coeptis Therapeutics Holdings, Inc. conducts its commercial operations primarily through its wholly-owned subsidiary Coeptis Pharmaceuticals, Inc.
Read More
Read More
Read More
To get the latest News articles and Press Releases, click on the learn more link below
